Keywords: efficacy, shown, merck, vioxx, co, cox-2, inhibitor
Efficacy Shown With Merck's Vioxx
Article | 21 April 1998
Merck & Co's COX-2 inhibitor, Vioxx (MK-966), has demonstrated efficacyin relieving the symptoms of osteo- and rheumatoid arthritis, as well as ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Italy's pharma market slump set to continue, warns GlobalData
